PI-RADS

Prostate Imaging Reporting and Data System

Current: PI-RADS v2.1 (2019)ACR / ESUR / AdMeTech Foundation (PI-RADS Steering Committee)
ProstateMR

PI-RADS is the standardized way radiologists acquire, interpret, and report prostate MRI to estimate how likely a lesion is to be clinically significant cancer. Built around multiparametric MRI — T2-weighted imaging plus diffusion-weighted and dynamic contrast-enhanced sequences — it assigns a 1-to-5 score reflecting that likelihood, helping decide who needs a biopsy and who can be spared one. It is jointly maintained by the ACR, the European Society of Urogenital Radiology, and the AdMeTech Foundation, and is the dominant prostate-MRI reporting standard.

Version history & what changed

  1. v2.12019Current

    The current refinement of v2. It tightened the transition-zone rules and diffusion-imaging thresholds, clarified handling of dynamic contrast enhancement, and addressed ambiguities readers hit with v2 — including a pathway to upgrade certain transition-zone lesions. The aim was better reproducibility, though in practice agreement changed little from v2.

  2. v22015

    The first version produced by the joint ACR/ESUR/AdMeTech committee. It replaced v1's additive scoring with a 'dominant sequence' approach — diffusion drives scoring in the peripheral zone, T2-weighting in the transition zone — and de-emphasized dynamic contrast, standardizing interpretation far more tightly than the original.

  3. v12012

    The original ESUR consensus that introduced a suspicion-scoring scheme for prostate mpMRI. It established the concept but left exactly how scores should be derived and combined loosely specified, which led to variable application.

How the system is structured

PI-RADS condenses the multiparametric MRI read into a single ordered score from 1 to 5 that broadly expresses how likely a lesion is to be clinically significant prostate cancer — low numbers meaning improbable, high numbers meaning probable. Crucially, the scoring is zone-aware: a 'dominant' sequence drives the assessment depending on whether the lesion sits in the peripheral or transition zone, with the other sequences playing supporting or tie-breaking roles. The system also standardizes how the MRI should be acquired and how the report is structured. Consult the official ACR/ESUR PI-RADS v2.1 document for the exact scoring criteria and thresholds.

  • 1 — Very lowClinically significant cancer is highly unlikely.
  • 2 — LowClinically significant cancer is unlikely.
  • 3 — Intermediate / equivocalGenuinely uncertain — the hard-to-call middle ground.
  • 4 — HighClinically significant cancer is likely.
  • 5 — Very highClinically significant cancer is highly likely, often with larger size or extracapsular features.

These are our plain-language summaries. For the exact criteria, thresholds, and management rules, see the official source.

Latest on PI-RADS

Body / AbdominalGeneralEducationTrainee

Review of Prostate Imaging Scoring Systems: From PI-RADS to PSMA-RADS

Nine structured prostate MRI scoring systems (PI-RADS, PRECISE, PI-RR, etc.) standardize interpretation across detection, surveillance, and post-treatment settings, improving agreement and facilitating evidence-based care.

BJR open
Body / AbdominalEducationTrainee

Implementing PI-QUAL: A Step-by-Step Guide to Prostate MRI Quality Assessment

The Prostate Imaging Quality (PI-QUAL) system provides a standardized framework to assess prostate MRI diagnostic adequacy. A new review outlines a stepwise implementation approach including multidisciplinary training, retrospective audits, protocol optimization, structured repo…

AJR. American journal of roentgenology
Body / AbdominalNuclear / MolecularResearchTrainee

Combining PI-RADS and PSA density could cut prostate biopsies by up to 20%

A study in 972 men externally validated the PROMOD biopsy strategy. PI-RADS 4-5 or PI-RADS 3 with a PSA density >0.15 avoided 18-20% of biopsies while missing 5-8% of clinically significant cancers. A more conservative approach (PI-RADS 4-5 or PI-RADS 3 with PSA density >0.10) a…

Research and reports in urology
Body / AbdominalMusculoskeletal (MSK)AI / InformaticsResearch

Hip prosthesis artifacts degrade deep-learning prostate MRI diagnosis

In prostate MRI, moderate-to-severe hip prosthesis artifacts degraded all three deep-learning models (AUC 0.62–0.71) compared with exams without prostheses (AUC 0.74–0.81), while radiologist PI-RADS performance held up better (AUC 0.77–0.79 across artifact categories).

Abdominal radiology (New York)

How it compares

PI-RADS is the prostate-MRI analogue of BI-RADS and the dominant standardized scheme, but it isn't the only approach: many centers also use Likert scoring, which lets the reader fold in clinical context (PSA, prior history) and weigh all sequences more flexibly, and which sometimes shows higher specificity in head-to-head work. Compared with its own past, today's PI-RADS abandoned v1's additive scoring in favor of the v2 dominant-sequence model, then fine-tuned it in v2.1. As of mid-2026 there is open disagreement about whether a version 3 is warranted: proponents point to the weakly performing transition-zone pathway and to category labels that don't match observed cancer prevalence, while others argue the evidence base isn't yet mature enough to justify another revision.

Evidence & controversy

A large 2024 systematic review and meta-analysis found PI-RADS v2.1 highly sensitive but only moderately specific for clinically significant cancer, with per-category cancer rates climbing steeply across the 1–5 scale. Reproducibility is moderate and experience-dependent, with pooled inter-reader agreement around kappa 0.6 and little measurable improvement from v2 to v2.1. PI-RADS is now embedded in major guidelines and routine practice for biopsy decision-making, but documented limitations include low specificity (driving false positives), the management dilemma of equivocal category 3 lesions, and unvalidated transition-zone rules — shortcomings that frame the current debate over whether to revise the system.

Frequently asked questions

What does a PI-RADS score mean?
It's a 1-to-5 estimate of how likely a prostate MRI lesion is to be clinically significant cancer — 1 is very unlikely, 5 is very likely — used to guide whether a biopsy is needed.
Does PI-RADS 3 mean I need a biopsy?
Category 3 is the equivocal middle ground, and the most debated. Whether to biopsy often depends on other factors (PSA density, prior biopsy, patient preference) rather than the score alone.
Is there a PI-RADS 6 like BI-RADS?
No. PI-RADS uses a 1-to-5 scale only; it does not have a 'biopsy-proven cancer' category the way BI-RADS does.
What's the current version, and is a version 3 coming?
The current version is v2.1, from 2019. There is active debate about a possible version 3, but as of mid-2026 none has been released.
How is PI-RADS different from a Likert score?
PI-RADS follows fixed, zone-specific rules and largely ignores clinical data when scoring; Likert lets the radiologist incorporate clinical context and judgment, which can change specificity.

Glossary

mpMRI (multiparametric MRI)
Prostate MRI combining T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences.
csPCa (clinically significant prostate cancer)
Cancer aggressive enough to matter clinically (typically Grade Group 2 or higher); what PI-RADS is designed to flag.
DWI / ADC
Diffusion-weighted imaging and its apparent diffusion coefficient map; the dominant sequence for peripheral-zone scoring.
DCE
Dynamic contrast-enhanced imaging; a supporting sequence used mainly to upgrade certain peripheral-zone lesions.
Peripheral zone / transition zone
The two main prostate regions PI-RADS scores differently, each with its own 'dominant' sequence.
Dominant sequence
The MRI sequence that primarily determines the score in a given zone (DWI in PZ, T2W in TZ).
ESUR / AdMeTech
The European Society of Urogenital Radiology and the AdMeTech Foundation — co-developers of PI-RADS alongside the ACR.

Resources & links

Written by RadPigeon Editorial Team, Radiology news editorial teamMedical review pending
Last reviewed: 29 Jun 2026Last changed: 29 Jun 2026

RadPigeon is an independent radiology news digest and is not affiliated with or endorsed by ACR / ESUR / AdMeTech Foundation (PI-RADS Steering Committee). “PI-RADS” is a trademark of its owner and is named here only to refer to the system. Always consult the official source for the exact, current criteria.